Evaluating Reduced Blood Monitoring Frequency and the Detection of Hematological Abnormalities in Clozapine-Treated Patients With Schizophrenia: A Chart Review Study From the COVID-19 Pandemic
- PMID: 38984851
- PMCID: PMC11908850
- DOI: 10.1093/schbul/sbae113
Evaluating Reduced Blood Monitoring Frequency and the Detection of Hematological Abnormalities in Clozapine-Treated Patients With Schizophrenia: A Chart Review Study From the COVID-19 Pandemic
Abstract
Background and hypothesis: In response to Health Canada's March 2020 directive, patients on clozapine for over 12 months were allowed to extend hematological testing intervals from 4 to 8 weeks during the COVID-19 pandemic. We hypothesized that this change would not affect the timely detection of hematological abnormalities in patients with severe mental illness.
Study design: A chart review was conducted of patients at the Royal Ottawa who were prescribed clozapine from March 2019 to March 2021. We analyzed clinical and hematological data from electronic health records and Clozaril Support and Assistance Network database to compare occurrences of hematological abnormalities [leukopenia (white blood cell count <3.5 × 109/L) and agranulocytosis (absolute neutrophil count <0.5 × 109/L)] from March 17, 2020 to March 16, 2021, between standard and extended monitoring protocols using binomial logistic and zero-inflated negative binomial regressions.
Study results: Of 621 patients, 196 were on extended blood monitoring, and 425 followed standard blood monitoring. Clozapine dose did not differ between groups (standard: 370 ± 201 mg; extended: 352 ± 172 mg; P = .14, ds = 0.10). Clozapine treatment duration up to March 2021 was 12.6 ± 8.3 years, with the extended group (10 ± 7.9 years) having a significantly (P < .01, ds = 0.50) shorter duration than the standard (14 ± 8.2 years). Extended monitoring did not significantly impact likelihood of detecting hematological abnormalities (OR = 0.83, 95% CI [0.58,1.41], P = .55) after controlling for age, sex, total bloodwork, and other psychotropics associated with neutrophil counts (ie, valproate, olanzapine). No patient on the extended regimen developed agranulocytosis.
Conclusions: Reducing blood monitoring frequency in patients on clozapine for more than 12 months did not compromise detection of hematological abnormalities.
Keywords: COVID-19; agranulocytosis; blood cell count; clozapine; drug monitoring; schizophrenia.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.
Similar articles
-
Clozapine-induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine.Hum Psychopharmacol. 2020 Jul;35(4):e2739. doi: 10.1002/hup.2739. Epub 2020 May 18. Hum Psychopharmacol. 2020. PMID: 32420645
-
Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand.Asian J Psychiatr. 2019 Mar;41:13-16. doi: 10.1016/j.ajp.2019.03.002. Epub 2019 Mar 5. Asian J Psychiatr. 2019. PMID: 30856469
-
No adverse events were observed in clozapine-treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan.Neuropsychopharmacol Rep. 2021 Jun;41(2):179-184. doi: 10.1002/npr2.12166. Epub 2021 Feb 19. Neuropsychopharmacol Rep. 2021. PMID: 33606356 Free PMC article.
-
Clozapine: the commitment to patient safety.J Clin Psychiatry. 1999;60 Suppl 12:39-42. J Clin Psychiatry. 1999. PMID: 10372610 Review.
-
Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.J Psychiatr Pract. 2014 Jan;20(1):50-8. doi: 10.1097/01.pra.0000442937.61575.26. J Psychiatr Pract. 2014. PMID: 24419309 Review.
Cited by
-
The Safety of 12-Weekly Monitoring of Neutrophil Count in Long-Term Clozapine Patients.Acta Psychiatr Scand. 2025 Sep;152(3):187-192. doi: 10.1111/acps.13818. Epub 2025 May 3. Acta Psychiatr Scand. 2025. PMID: 40844120 Free PMC article.
References
-
- Siskind D, McCartney L, Goldschlager R, Kisely S.. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392. - PubMed
-
- Horacek J, Bubenikova-Valesova V, Kopecek M, et al.. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389–409. - PubMed
-
- Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, Enns MW.. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996–2006. Psychiatr Serv. 2008;59(5):547–553. - PubMed
-
- Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O’Sullivan D.. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483–488. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical